Trial Profile
A two week treatment, multi-center, randomized, openlabel, assessor blinded, parallel group study of QAE397 400 g, o.d. QAE397 1200 g o.d. , budesonide 100 g, o.d. , or budesonide 400 g, b.i.d. delivered via SDDPI in moderate to severe asthmatic patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2011
Price :
$35
*
At a glance
- Drugs QAE 397 (Primary) ; Budesonide
- Indications Asthma
- Focus Pharmacodynamics
- 29 Jun 2011 New trial record